This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.

Steven Kelly

Vice President

Steve has over 20 years of experience working in health technology assessment, evidence-based medicine, health economics, and pricing and market access within the pharmaceutical industry.

Prior to joining CRA, Steve was Senior Director for Global Health & Value at Pfizer responsible for global market access of hospital products in Pfizer’s established products business. His expertise has focused on pricing and market access in Europe, with in-depth experience of health technology assessment (HTA) in the UK. He has worked on a broad range of therapeutic areas throughout the lifecycle from Phase 2 to post loss of exclusivity.

Related capabilities
Related capabilities

Selected engagements

  • 01
    Long-term strategic partner in bladder cancer
    We formed a long-term, multi-project partnership with a leading manufacturer that was looking to establish its new product as standard of care in bladder...
    View engagement
  • 02
    Evaluating the potential impact of cross-border healthcare for gene therapies
    CRA's Rare Disease team evaluated the dynamics of cross-border healthcare using secondary research to explore current precedence and/or previous product...
    View engagement
  • 03
    Global pricing and access strategic issues assessment for rare diseases gene therapy portfolio
    CRA delivered recommendations on optimization and risk mitigation for gene therapy pricing strategy implementation...
    View engagement

Latest insights

Recent events

Credentials

Get In Touch
Steven Kelly
London +44-207-664-3748 skelly@crai.com